OSE Immunotherapeutics Receives Second Positive Recommendation for Lung Cancer Trial
OSE Immunotherapeutics announced it has received a second positive recommendation from its Data Monitoring Committee (IDMC) for the Phase 3 ARTEMIA trial evaluating Tedopi in non-small cell lung cancer.
OSE Immunotherapeutics has received a second positive recommendation from the independent Data Monitoring Committee (IDMC) for its Phase 3 ARTEMIA study evaluating Tedopi for non-small cell lung cancer. The IDMC's recommendation is based on safety data and the trial's prognosis.
The committee recommended that the study continue without modifications. The ARTEMIA trial aims to demonstrate the efficacy of Tedopi in combination with standard chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer.
Tedopi is an immunotherapy developed by OSE Immunotherapeutics based on a Toll-like receptor 2 (TLR2) agonist molecule. It is designed to stimulate the immune system to recognize and attack cancer cells.
OSE Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunotherapies for cancer and autoimmune diseases. The company maintains a pipeline of clinical and preclinical development projects.